HighTide Therapeutics Inc (2511.HK)
HKD 1.8
(5.88%)
HKD 1.8
(5.88%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 99.39 Million CNY | -93.3% |
| 2022 | 1.48 Billion CNY | 17.13% |
| 2021 | 1.26 Billion CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 73.11 Million CNY | 0.71% |
| 2024 Q1 | 73.11 Million CNY | -24.98% |
| 2023 Q3 | 92.26 Million CNY | -95.21% |
| 2023 Q2 | 1.92 Billion CNY | 7.76% |
| 2023 FY | 99.39 Million CNY | -93.3% |
| 2023 Q1 | 1.78 Billion CNY | 20.47% |
| 2023 Q4 | 99.39 Million CNY | 7.73% |
| 2022 Q4 | 1.48 Billion CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 152.81 Million HKD | 34.96% |
| CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 98.592% |